Presentation is loading. Please wait.

Presentation is loading. Please wait.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele.

Published byJosefina Rocío Ramírez Ortíz Modified over 5 years ago

Similar presentations

Presentation on theme: "EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele."— Presentation transcript:

1 EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele Milella, MD, Carmen Nuzzo, MD, Emilio Bria, MD, Isabella Sperduti, MS, Paolo Visca, MD, Fiamma Buttitta, MD, PhD, Barbara Antoniani, MS, Roberta Merola, PhD, Alain Gelibter, MD, Federica Cuppone, MD, Valerio D'Alicandro, MS, Anna Ceribelli, MD, Massimo Rinaldi, MD, Anna Cianciulli, PhD, Lara Felicioni, PhD, Sara Malatesta, PhD, Antonio Marchetti, MD, PhD, Marcella Mottolese, PhD, Francesco Cognetti, MD  Journal of Thoracic Oncology  Volume 7, Issue 4, Pages (April 2012) DOI: /JTO.0b013e31824a8bde Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Study flow diagram and EGFR-TKI treatment allocation by molecular subgroup. NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; pAKT, phosphorylated AKT; HER-2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; TKI, tyrosine kinase inhibitor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824a8bde) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Outcome upon EGFR-TKI treatment in prospectively selected molecular and clinical subgroups. G1: mutated EGFR; G2: EGFR mutation negative or unknown, amplified EGFR gene, and/or high-grade chromosome no. 7 polysomy; G3: EGFR mutation/amplification negative/unknown, positive EGFR and/or pAKT IHC staining; G4: molecular profile negative for parameters defining groups 1 to 3 or not evaluable, adenocarcinoma or bronchoalveolar carcinoma histology, and no smoking history. A, Overall response rate according to RECIST criteria. B, Disease control rate (DCR), defined as the proportion of patients achieving an objective response or disease stabilization for ≥6 months. C, Kaplan-Meier estimation of progression-free survival (PFS), D, Kaplan-Meier estimation of overall survival (OS). EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; pAKT IHC phosphorylated AKT immunohistochemistry; PR, partial response; SD, stable disease; PD, progressive disease. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824a8bde) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Kaplan-Meier survival plots for PFS (top panels) and OS (bottom panels) after epidermal growth factor receptor-tyrosine kinase inhibitor therapy according to clinical/molecular factors found to be independent predictors of outcome at multivariate analysis (see also Table 1). Log-rank p values are shown for each individual panel. EGFR, epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival; and pAKT, phosphorylated AKT. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824a8bde) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Individual patient probability of 1-year overall survival according to different combinations of clinical/molecular factors found to be independent predictors of outcome upon EGFR-TKI treatment at multivariate analysis (see also Table 1). Accuracy of the multivariate model used to calculate individual patient probability of outcome was assessed by receiver-operating characteristic analysis (area under the curve 0.73; 95% CI, 0.63–0.81, see Supplemental Figure S3, Supplemental Digital Content 5, EGFR, epidermal growth factor receptor; pAKT, phosphorylated AKT. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824a8bde) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 5 Kaplan-Meier survival plots for PFS (left column) and OS (right column) after first-line chemotherapy according to clinical/molecular factors found to be independent predictors of outcome at multivariate analysis (Supplemental Table S3, Supplemental Digital Content 7, Log-rank p values are shown for each individual panel. PFS, progression-free survival; OS, overall survival; HER-2, human epidermal growth factor receptor 2; pAKT, phosphorylated AKT; TKI, tyrosine kinase inhibitor; pos, positive; neg, negative. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824a8bde) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele."

Similar presentations

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort  Michèle Beau-Faller, MD,
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer  Martin Reck, MD, PhD, Normand Blais,

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer  Martin Reck, MD, PhD, Normand Blais,
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  Antonio Marchetti, MD, PhD,

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  Antonio Marchetti, MD, PhD,
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma  Isabelle Opitz, MD, Martina Friess,

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma  Isabelle Opitz, MD, Martina Friess,

Similar presentations

Ads by Google